An assessment of the provider financial risk impacts of adoption of biosimilars in the Medicare Oncology Care Model. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
The Food and Drug Administration issued a final guidance on Monday for how and when existing clinical data should be used to support pediatric medical device indications and labeling. The guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results